ClinicalTrials.gg
CompletedNCT05298774Updated Aug 3, 2025Results posted

Myoelectric Activity Following Colorectal Surgery and Return of Bowel Function

An interventional study of G-tech WPS in Gastrointestinal Diseases, Ileus Paralytic and Ileus, sponsored by Yale University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-03.

Primary conditionIleusRegistry: Gastrointestinal DiseasesReclassifiedWhy we changed it
Registry
Gastrointestinal Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ileus
Why
  1. The study's listed conditions name Ileus, a narrower term within Gastrointestinal Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Yale University · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
77
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to determine if the myoelectrical measurements made by the G-Tech Wireless Patch System correlate with clinical markers of postoperative recovery such as passage of flatus/bowel movement, oral tolerance of diet and discharge readiness. Subsequently the data will be studied to establish which information in the signals is important in determining when to feed patients and possibly discharge them.

These pilot prospective, open clinical studies suggests that myoelectrical activity, measured on the abdominal surface with a noninvasive wireless patch system, carries predictive value in determining time to feeding and time to flatus following open abdominal surgery. Having such information in advance of clinical measures could facilitate timely interventions, be it early feeding or delaying feeding as dictated by the patient's unique recovery profile. The G-Tech Wireless Patch System would provide a unique insight into the process allowing for a tailored protocol that could improve patient satisfaction and optimize recovery. The system could also enable feedback on the impact to the overall gastrointestinal myoelectrical activity of medications, particularly opioids, used for pain management that are known to inhibit gastrointestinal function by disrupting the normal recovery patterns of colonic motility.23-25 While it remains to be seen, in addition to predicting time to flatus/bowel movement early on, the ability to continue monitoring the patient may allow one to predict onset of secondary complications, such as wound infections or anastomotic leaks, that are associated with ileus. Similarly, given the wireless noninvasive nature of the system the patients could be discharged home with the patches, whereby they would serve as a remote monitoring tool. This could be particularly useful in cases where the patients may have been discharged early and may be at a high risk for readmission. The system would then send updates/alerts to the care team for management and potentially avoid preventable readmissions.

Read the detailed description

Gastrointestinal recovery after any visceral surgery is a complex dynamic process with multiple factors ranging from complexity of the surgery, degree of bowel handling and preoperative comorbidities affecting whether the recovery happens over few days, or is a slow prolonged affair lasting weeks. Delays in the gastrointestinal recovery process or ileus is accompanied by distention of the abdomen, pain, nausea, vomiting and the inability to tolerate oral feeding. Interventions to alleviate the ileus/distention include insertion or reinsertion of a nasogastric tube, instating nil per os and, if necessitated, parenteral nutrition. All of these factors contribute not only to patient discomfort, but extend length of stay (LOS), increase hospital resource utilization and thereby add to overall costs.

Clinically, the markers of gastrointestinal recovery are noted by passage of flatus, defecation and the ability to tolerate solid food without significant nausea and vomiting. Passage of stool or flatus - considered a surrogate for intestinal and anastomotic continuity - is often used as the trigger to start stepwise dietary orders with the patient's ability to tolerate each step marking their readiness for the subsequent meal. Fast-track and Enhanced Recovery After Surgery (ERAS) programs that promote early feeding in advance of these clinical markers, along with opioid sparing techniques and use of minimally invasive procedures have been shown to be safe and beneficial for many patients by demonstrating earlier recovery and shorter length of stay. However, it has also been shown that, for as many as 25% of cases, the strategy does not work as noted earlier, with the need for reinsertion of the nasogastric tube and reinstating nil per os status. In a recent study of 513 consecutive colorectal patients who were on an ERAS protocol, 128 patients (24.7%) needed postoperative reinsertion of nasogastric tube at the 3.9±2.9 postoperative day. This suggests that, while early postoperative feeding is beneficial to patients in whom recovery is on track, it does not work in cases where patients are not ready for it.

At present, there is no reliable measurement that can predict gastrointestinal recovery/diet readiness for patients in advance of these clinical markers that may allow for interventions or fast-track programs to facilitate timely recovery. Auscultation for return of bowel sounds, long part of the standard of care, is controversial in its usefulness to indicate recovery. Bowel sounds have shown to have poor correlation with flatus/defecation and have proved unsuccessful in guiding diet interventions.

Smooth muscle electrical activity on the other hand is directly related to gastrointestinal function and motility. Researchers have previously shown a 1:1 correlation between electrical and mechanical (contractile) events in the colon with internally placed electrode-strain gauge force transducers. Electrical activity in the colon has been reported across a wide range of frequencies ranging from 0 to 40 cycles per min (cpm)). Condon et. al have documented the progressive return of colonic electrical related to resolution of postoperative ileus and clinical recovery following surgery. These measurements have been performed using electrodes placed internally during surgery, a major impediment towards broader use of such technology.

G-Tech Medical has developed a noninvasive wireless patch system that measures electrical activity from the gastrointestinal smooth muscles on the abdominal surface. This technology has been studied as part of several non-significant risk IRB approved studies in both adults and pediatric populations to evaluate the patterns of gastrointestinal myoelectrical signals following surgery. The studies demonstrate that signals measured by the G-Tech Wireless patches correlate with clinical markers of postoperative recovery such as time to feeding and time to flatus following pancreaticoduodenectomy and general abdominal surgeries respectively. The study in patients undergoing pancreaticoduodenectomy procedures was conducted in collaboration with researchers at Stanford University. The study demonstrated that measurement of gastric activity beginning immediately after pancreaticoduodenectomy with the G-Tech Wireless Patch System, based on the measured spectral peak near 3 cpm, could distinguish patients with shorter or longer times to diet readiness. The study demonstrated the potential utility of the G-Tech Patch System in providing objective data to identify patients who are progressing as well as, or better than expected, and those who are at risk for delayed gastric emptying. In another open, prospective study, researchers examined the use of the G-Tech Wireless Patch System in predicting time to first flatus by looking at colonic myoelectrical activity following general abdominal surgeries.21 Patients with early flatus had stronger early colonic activity than patients with late flatus. At 36 h post-surgery, a linear fit of time to flatus vs cumulative colonic myoelectrical activity predicted first flatus as much as 5 days (± 22 h) before occurrence.

These pilot prospective, open clinical studies suggests that myoelectrical activity, measured on the abdominal surface with a noninvasive wireless patch system, carries predictive value in determining time to feeding and time to flatus following open abdominal surgery. Having such information in advance of clinical measures could facilitate timely interventions, be it early feeding or delaying feeding as dictated by the patient's unique recovery profile. The G-Tech Wireless Patch System would provide a unique insight into the process allowing for a tailored protocol that could improve patient satisfaction and optimize recovery. The system could also enable feedback on the impact to the overall gastrointestinal myoelectrical activity of medications, particularly opioids, used for pain management that are known to inhibit gastrointestinal function by disrupting the normal recovery patterns of colonic motility. While it remains to be seen, in addition to predicting time to flatus/bowel movement early on, the ability to continue monitoring the patient may allow one to predict onset of secondary complications, such as wound infections or anastomotic leaks, that are associated with ileus. Similarly, given the wireless noninvasive nature of the system the patients could be discharged home with the patches, whereby they would serve as a remote monitoring tool. This could be particularly useful in cases where the patients may have been discharged early and may be at a high risk for readmission. The system would then send updates/alerts to the care team for management and potentially avoid preventable readmissions.

The purpose of the Phase 1 study is to determine if the myoelectrical measurements made by the G-Tech Wireless Patch System correlate with clinical markers of postoperative recovery such as passage of flatus/bowel movement, oral tolerance of diet and discharge readiness. Subsequently the data will be studied to establish which information in the signals is important in determining when to feed patients and possibly discharge them.

02

Conditions studied

  • Gastrointestinal Diseases
  • Ileus Paralytic
  • Ileus

Browse trials for

03

In context

Ileus Reclassified

167 studies on the registry are indexed under Ileus; 23 are open to participants now.

This study's enrollment of 77 is below the median of 90 across 138 interventional studies indexed under Ileus.

Browse Ileus studies →

Lead sponsor

Yale University is the lead sponsor of 1,770 studies on the registry; 294 are open to participants now.

Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.

Compared within Ileus, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Gastrointestinal Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide
  2. Eighteen (18) years of age or older
  3. Subject is willing and able to follow all study requirements
  4. Subject has undergone or will undergo a laparoscopic or open colorectal surgery with resection and anastomosis

Exclusion criteria

Exclusion Criteria:

  1. Subject is pregnant or suspects pregnancy.
  2. Known allergy to medical grade adhesive.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    Postoperative recovery with G-tech WPS

    Device: G-tech WPS

Interventions

  • DeviceG-tech WPS

    G-tech WPS patches applied and activated within 4 hours of surgery

06

What researchers measure

Primary outcomes

  1. GI Functional Recovery

    Time to return of flatus or bowel movement after colorectal surgery

    Time frame: 30 days after index surgery

Secondary outcomes

  1. Postoperative Ileus

    Occurrence of postoperative ileus after colorectal surgery

    Time frame: 30 days after index surgery

  2. Readmission With Ileus

    Occurrence of readmission with postoperative ileus after colorectal surgery

    Time frame: 30 days after index surgery

07

Results

Posted Aug 3, 2025
Limitations and caveats
The study is limited by a short follow-up duration restricted to in-patient settings and aligning myoelectric readings with clinical symptoms is under-powered.

Participant flow

Participant flow — Overall Study
MilestonePostoperative Recovery With G-tech WPS
Started77
Completed68
Not completed9
Withdrew: Physician decision3
Withdrew: Withdrawal by subject2
Withdrew: Lost to follow-up3
Withdrew: Screen failure1

Outcome measures

PrimaryGI Functional Recovery

Time to return of flatus or bowel movement after colorectal surgery

Time frame:
30 days after index surgery
Reported as:
Mean · hours
GI Functional Recovery
hoursPostoperative Recovery With G-tech WPS
GI Functional Recovery47.94 ± 30.78
SecondaryPostoperative Ileus

Occurrence of postoperative ileus after colorectal surgery

Time frame:
30 days after index surgery
Reported as:
Count of participants · Participants
Postoperative Ileus
ParticipantsPostoperative Recovery With G-tech WPS
Postoperative Ileus6
SecondaryReadmission With Ileus

Occurrence of readmission with postoperative ileus after colorectal surgery

Time frame:
30 days after index surgery
Reported as:
Count of participants · Participants
Readmission With Ileus
ParticipantsPostoperative Recovery With G-tech WPS
Readmission With Ileus0

Adverse events

Collected over 14 days of follow-up after index surgery. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Postoperative Recovery With G-tech WPS0/77 (0%)0/77 (0%)0/77 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Postoperative Recovery With G-tech WPS
Mean62.42 ± 12.72
Sex: Female, Male
Sex: Female, Male(Participants)Postoperative Recovery With G-tech WPS
Female40
Male37
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Postoperative Recovery With G-tech WPS
Hispanic or Latino6
Not Hispanic or Latino70
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Postoperative Recovery With G-tech WPS
American Indian or Alaska Native1
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American4
White67
More than one race1
Unknown or Not Reported1
Height
Height(cm)Postoperative Recovery With G-tech WPS
Mean170.27 ± 10.60
Weight
Weight(kg)Postoperative Recovery With G-tech WPS
Mean79.88 ± 19.43
08

Study locations

1 site
  • Yale New Haven Hospital
    New Haven, Connecticut 06519, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Sep 2024, 27 months.

Results were first posted in Aug 2025, 11 months after primary completion.

Of 40 non-industry interventional studies with no phase under Ileus, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 53. This study's 27 months is above that.

Counting every sponsor, half of 40 studies reached it within 19 months; a quarter within 7 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2022
First posted
Mar 28, 2022
StartActual
Jun 1, 2022
Primary completionActual
Sep 1, 2024
CompletionActual
Sep 1, 2024
Results first posted
Aug 3, 2025
Last update
Aug 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05298774
Lead sponsor
Yale University
Collaborators
G-Tech Corporation
Responsible party
Sponsor
First posted
Mar 28, 2022
Start date
Jun 1, 2022
Primary completion
Sep 1, 2024
Completion
Sep 1, 2024
Results posted
Aug 3, 2025
Last update
Aug 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion